2023 Independent Medical Education Request for Proposal

Issue Date: February 15, 2023

The *Independent Medical Education team at Genentech, a member of the Roche Group,* invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposal (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp) and the Society for Academic Continuing Medical Education (SACME). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on http://funding.gene.com)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech's Independent Medical Education team. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	- U.S. based education provider - Registered account in gFRS - Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 6 weeks to complete a full application	March 29, 2023
Step 2	After 1 week, respective Genentech Medical Education Managers will review and provide notification of final decisions via email	April 5, 2023
Step 3	Due to the timeliness of this education, we ask that all programs within the submission are launched by July 5, 2023	July 5, 2023

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Genentech
A Member of the Roche Group

Currently Available RFP Focus Area:

Focus	Opportunity
Therapeutic Area: Oncology	The clinical data for non-small cell lung cancer (NSCLC) is ever evolving at a rapid pace. Healthcare providers must be aware of the role of PD-1/PD-L1 in treatment selection in adjuvant therapy for NSCLC.
Disease: Lung Cancer	Testing of lung cancer specimens is important to determine if a cancer immunotherapy may/or may not be appropriate for a patient based on their individual disease characteristics.
Learning Audience: Community-based medical oncologists	Genentech is seeking education focused on helping community practitioners distinguish between therapeutic options in adjuvant NSCLC and increase knowledge and competence related to how testing plays a crucial role in treatment selection.
Educational Format: Grand Rounds	**References:**
Support Available: Up to $250,000	1. Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit Rev Oncol Hematol. 2021 Jan;157:103194. doi: 10.1016/j.critrevonc.2020.103194. Epub 2020 Dec 11. PMID: 33316418.
Knowledge- and Competence-based Regional and Local Education *(Understanding & Addressing national or local gaps & emerging data)*	2. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2023 Non-Small Cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed Date: 2/13/2023. 3. Doximity. Physician Learning Preferences. Oct 2022. https://c8y.doxcdn.com/image/upload/Press%20Blog/Research%20Reports/Doximity-Physician-Learning-Report-2022.pdf